The India/SA WTO TRIPS proposal is an IP waiver including trade secrets/know-how (not just patents). So ‘abolish the patents’ is not a magical slogan but shorthand for what India/SA have called for since late 2020:
waive patents + share knowhow + build production in global south
The complexities of vaccine production have always been evident & undeniable. But it was clear by Dec 2020 that relying on the pharma market production approach was not going to produce sufficient volumes to vaccinate the world. Even the EU has struggled to obtain doses.
From Jan the US/EU/UK should have thrown the entirety of their pharma-industrial capacity into (I) making vaccines in the West; and (II) helping to build capacity in the global south. A lot has been done on (I) but very little on (II).
The nightmare in India was foreseeable. Modi deserves a lot of blame. But the West has the power to do much more & is *failing* to do so. The US/UK/EU must help build capacity via tech transfer in the global south *now* or the India crisis will be repeated all over South Asia
The India/SA TRIPS proposal is political and aims to put pressure on the West to do what is necessary. So far, voluntary measures have been totally insufficient. The WTO TRIPS IP waiver proposal is very far from ‘magical thinking’ - it is a rational response to a global crisis.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
A few critical comments on this new paper by @mercuriobryan on IP & COVID-19 vaccines/treatments. This is, I think, the first major academic paper that argues against the India/SA TRIPS WTO waiver so it deserves attention.
1) The paper accepts here that the TRIPS IP waiver may accelerate distribution of COVID-19 vaccines in the short term, but is concerned that the waiver could undermine the IP system’s incentives for R&D. What does ‘short term’ mean here?
2) The paper seems to downplay the ‘short term’ risk to developing countries by noting that Covax will begin providing 2billion doses to developing countries in the first half of 2021.